HC Wainwright Reiterates “Neutral” Rating for Sutro Biopharma (NASDAQ:STRO)
Sutro Biopharma (NASDAQ:STRO – Get Free Report)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $2.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 90.48% from the stock’s current price. […]
Sutro Biopharma (NASDAQ:STRO – Get Free Report)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $2.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 90.48% from the stock’s current price. […]
